Cytokinetics is pushing a promising heart-focused drug toward the finish line, but the biggest slowdown may come after approval as insurers and country-by-country payment decisions drag out the rollout. If the company can navigate that red tape without needing too much new funding, it could still build a broader set of treatments—yet setbacks with its lead drug or stronger rivals could quickly change the story.Read more
A small drug developer is betting on a new heart medicine that could reshape how certain patients are treated, with doctors already paying close attention to its trial results. But the whole story hinges on regulators giving the green light and the company proving it can compete and launch smoothly in a crowded market.Read more
A little-known heart drug could quickly move from “promising” to a go-to option as new study results shake up how doctors treat a hard-to-manage condition. But the upside comes with big risks, including reliance on one lead program, possible approval delays, and rising costs as rivals crowd the field.Read more
No trending discussion available.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
